Genfit: takeover rumors and promising results for its treatment
Genfit's stock rises 8% on June 23, fueled by takeover rumors and positive data on its GNS561 treatment.
Published 3sem1 sourceMajorupdated 4j
Lire en français
≈ 22s
The fact
The French lab, specializing in liver diseases, could attract interest from Ipsen or other players.
Investors are watching for a possible official announcement in the coming days.
Click the link to read an article on the topic: